“ My passion is protecting complex, cutting–edge biotech and pharma innovations as they emerge from laboratories to commercialization, ultimately reaching millions of people around the world.
Intellectual versatility combined with incisive, pragmatic counseling and business acumen is the hallmark of Catherine’s practice.
Catherine helps emerging and established companies through the challenging process of obtaining patents, and provides strategic, effective portfolio counseling and management, as well as strategic advice surrounding freedom of operation and other forms of IP assessment. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including:
She also has significant experience in a wide spectrum of technology areas, including biologics (such as antibodies and polypeptides), nucleic acids, precision medicine, diagnostics, cell therapy including T cell technologies, such as chimeric antigen receptors, drug formulation technologies, drug delivery technologies, such as nanotechnologies, microfluidics, drug screening systems, AI solutions for life sciences including discovery platforms, amplification technologies, genetic screening, sequencing technologies including next generation sequencing, regenerative medicine, nutraceuticals, spectroscopy, and organic chemistry, including small molecule drugs.
Catherine’s unique background, ability to integrate IP with a given business model to translate into meaningful valuation, risk assessment and advice, and highly effective communication skills in critical settings such as R&D, all phases of product development, and investment contexts, enable her to provide effective, creative solutions to the significant challenges often faced by clients. Catherine is an acquisition and value enhancement driver as well, a critical conduit for companies as they grow from startup through IPO, exit, and beyond.
IP Leadership for Transactions, Financings, and Acquisitions. Catherine’s practice also includes due diligence evaluation and counseling in the context of venture investment assessments and in connection with public and private financing, spin-offs, partnerships, and mergers and acquisitions, where her IP strategies have helped drive the value of multibillion dollar deals.
Representative transactions resulting from Catherine’s leadership include:
Catherine was retained by Johnson & Johnson, BMS, Pfizer, Celgene, and Juno (following the acquisitions of both by BMS) for ongoing patent strategy and counseling work on the existing patent portfolios and with expanded representation of the parent companies following these acquisitions. Other representative transactions where her astute leadership has proved invaluable include:
Strategist in Legal Challenges and a Key Member of Litigation Teams. In addition to helping create value and commercialize her clients’ technologies, Catherine devises strategies and defenses to fortify their patents in the event of legal challenges by competitors. Accordingly, she renders advice on all aspects of patent positioning, including opinions on patentability, validity, freedom of operation, infringement, and competitor IP evaluation. She also works in the area of third–party challenges, such as inter partes review (IPR) and oppositions.
A Recognized Leader. From 2006 through 2009, Catherine served as the chair of the firm’s Patent Prosecution & Counseling Group and co-chair of the firm’s Intellectual Property Group. Chambers USA noted that Catherine “maintains a strong reputation for her capabilities advising biotechnology clients on portfolio management and other IP matters,” while clients note that she is “a great strategic thinker, great at flagging the high–level questions and brings a good business perspective,” and praise her for “bring[ing] a good business perspective to IP efforts which is not always evident with other IP attorneys.” Catherine has also received the following awards and accolades:
Catherine is patent counsel to numerous publicly traded and privately held companies, with many new client relationships resulting from her strong reputation in the life sciences industry. A selection of her representative matters include the following:
Chambers Global 2021
Daily Journal 2019
Legal Media Group 2018
Chambers USA 2013–2021
Chambers USA 2018–2021
Legal 500 US 2012–2021
Managing Intellectual Property 2013, 2014, 2018, 2019, 2020, 2021
Managing Intellectual Property 2018–2020
Legal Media Group Life Sciences 2012–2020
Legal Media Group Life Sciences 2020
Daily Journal 2009–2021
The Recorder 2013, 2015, 2016, and 2017
IAM Patent 1000 2014–2017, 2021
Northern California Super Lawyers List 2012–2018
Super Lawyer’s Women’s Edition 2016–2018
Financial Times U.S. Innovative Lawyers report 2013
Silicon Valley Business Journal 2013
Euromoney Legal Media Group 2013
Managing Intellectual Property 2018-2021